IDDI organized a webinar on the Future of Cancer Clinical Trials.
Cancer clinical trials have been a major determinant of advances in medical oncology over the past 50 years. Both for patients participating in clinical trials and for future patients in clinical practice, successful clinical trials provide the cornerstone for improvements. However, oncology is well known for its relatively low success rates during the development of novel agents. Moreover, as in other areas of medicine, a crisis is currently affecting cancer clinical trials. The most salient features of this crisis are the declining efficiency and the prevailing unpredictability of outcomes of these essentially global enterprises. The rising costs of cancer clinical trials, coupled with longer times for completion and increased regulation, are probably at the root of the declining efficiency. Moreover, many of the factors that predict for a successful drug development process remain poorly understood. At the same time, our increased capacity to interrogate the biological features of tumors, coupled with advances in information and communications technology, promise to bring dramatic improvements in the future.
In this webinar, the speakers explored what they believe are the driving factors of change toward that future.
This webinar focused on the future of cancer clinical trials.
Our increased capacity to interrogate the biological features of tumors, coupled with advances in information and communications technology, promise to bring dramatic improvements in the future. In this webinar, the speakers explored what they believe are the driving factors of change toward that future.
SPEAKERS:
